Advertisement
Screener

YARROW BIOSCIENCE, INC. (YARW) Payments to Acquire Marketable Securities

1.3 / 5 stars · 17/67 Roast Me

YARROW BIOSCIENCE, INC. Payments to Acquire Marketable Securities

YARROW BIOSCIENCE, INC. (YARW) reported Payments to Acquire Marketable Securities of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-13

  • YARROW BIOSCIENCE, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
  • YARROW BIOSCIENCE, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
  • YARROW BIOSCIENCE, INC. payments to acquire marketable securities for the quarter ending 2025-06-30 was $9.57M, a 39.17% increase year-over-year.
  • YARROW BIOSCIENCE, INC. payments to acquire marketable securities for the quarter ending 2025-03-31 was $13.77M, a 9.23% decline year-over-year.
  • YARROW BIOSCIENCE, INC. payments to acquire marketable securities for fiscal 2023 was $62.35M.
  • YARROW BIOSCIENCE, INC. payments to acquire marketable securities for fiscal 2022 was $0.00.
Period endPayments to Acquire Marketable Securities 3 monthPayments to Acquire Marketable Securities 6 monthPayments to Acquire Marketable Securities 9 monthPayments to Acquire Marketable Securities 12 month
2026-06-30$0.00
derived: 10-Q 6 month − S-4/A 3 month · filed 2026-08-13
$0.00
10-Q · filed 2026-08-13
2026-03-31$0.00
S-4/A · filed 2026-06-03
2025-12-31$30.93M
S-4/A · filed 2026-06-03
2025-06-30$9.57M
derived: 10-Q 6 month − S-4/A 3 month · filed 2026-08-13
$23.34M
10-Q · filed 2026-08-13
$33.39M
derived: sum of 3 quarters · filed 2026-08-13
$61.81M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$13.77M
S-4/A · filed 2026-06-03
$23.81M
derived: sum of 2 quarters · filed 2026-06-03
$52.24M
derived: sum of 3 quarters · filed 2026-06-03
$59.12M
derived: sum of 4 quarters · filed 2026-06-03
2024-12-31$10.04M
derived: S-4/A 12 month − 10-Q 9 month · filed 2026-06-03
$38.47M
derived: sum of 2 quarters · filed 2026-06-03
$45.35M
derived: sum of 3 quarters · filed 2026-06-03
$60.52M
S-4/A · filed 2026-06-03
2024-09-30$28.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$35.30M
derived: sum of 2 quarters · filed 2025-08-14
$50.47M
10-Q · filed 2024-11-07
$112.83M
derived: sum of 4 quarters · filed 2025-08-14
2024-06-30$6.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$22.05M
10-Q · filed 2025-08-14
$84.40M
derived: sum of 3 quarters · filed 2025-08-14
$84.40M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$15.17M
10-Q · filed 2025-05-08
$77.52M
derived: sum of 2 quarters · filed 2025-05-08
$77.52M
derived: sum of 3 quarters · filed 2025-05-08
$77.52M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31$62.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
$62.35M
derived: sum of 2 quarters · filed 2025-03-06
$62.35M
derived: sum of 3 quarters · filed 2025-03-06
$62.35M
10-K · filed 2025-03-06
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$0.00
derived: sum of 2 quarters · filed 2024-11-07
$0.00
10-Q · filed 2024-11-07
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$0.00
10-Q · filed 2024-08-14
2023-03-31$0.00
10-Q · filed 2024-05-09
2022-12-31$0.00
10-K · filed 2024-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Cingulate Inc. (CING)United States$0.073B-2.64
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
XBiotech Inc. (XBIT)United States$0.066B-1.56
HYPERION DEFI, INC. (HYPD)United States$0.065B